ACADIA Pharmaceuticals (NASDAQ:ACAD) Given Maintains Rating at 1-800-FLOWERS.COM

1-800-FLOWERS.COM reiterated their maintains rating on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Rating) in a research report released on Monday morning, Benzinga reports.

A number of other analysts have also issued reports on the company. Citigroup boosted their target price on ACADIA Pharmaceuticals from $21.00 to $21.60 in a research report on Tuesday, May 9th. Mizuho restated a neutral rating and issued a $20.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Friday, April 14th. Canaccord Genuity Group upped their price objective on shares of ACADIA Pharmaceuticals from $24.00 to $26.00 and gave the company a buy rating in a research note on Tuesday, March 14th. Jefferies Financial Group increased their target price on shares of ACADIA Pharmaceuticals from $10.00 to $15.00 in a research note on Tuesday, March 14th. Finally, JMP Securities increased their price target on shares of ACADIA Pharmaceuticals from $22.00 to $23.00 and gave the stock an outperform rating in a report on Tuesday, May 9th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of Moderate Buy and a consensus target price of $25.43.

ACADIA Pharmaceuticals Stock Up 0.4 %

Shares of ACADIA Pharmaceuticals stock opened at $25.65 on Monday. ACADIA Pharmaceuticals has a twelve month low of $12.24 and a twelve month high of $25.73. The business has a 50-day moving average price of $20.37 and a 200 day moving average price of $18.44. The firm has a market cap of $4.17 billion, a PE ratio of -28.19 and a beta of 0.54.

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Rating) last issued its earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.06). The company had revenue of $118.46 million for the quarter, compared to analyst estimates of $120.29 million. ACADIA Pharmaceuticals had a negative return on equity of 35.70% and a negative net margin of 28.05%. The company’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.70) earnings per share. On average, sell-side analysts expect that ACADIA Pharmaceuticals will post -0.57 EPS for the current year.

Insider Buying and Selling

In related news, CEO Stephen Davis sold 3,851 shares of ACADIA Pharmaceuticals stock in a transaction on Friday, February 24th. The shares were sold at an average price of $18.78, for a total transaction of $72,321.78. Following the transaction, the chief executive officer now owns 91,727 shares in the company, valued at approximately $1,722,633.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, Director Bros. Advisors Lp Baker bought 209,053 shares of the firm’s stock in a transaction on Tuesday, May 23rd. The stock was purchased at an average price of $25.41 per share, for a total transaction of $5,312,036.73. Following the transaction, the director now owns 38,811,515 shares in the company, valued at $986,200,596.15. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Stephen Davis sold 3,851 shares of the company’s stock in a transaction dated Friday, February 24th. The stock was sold at an average price of $18.78, for a total transaction of $72,321.78. Following the completion of the transaction, the chief executive officer now owns 91,727 shares of the company’s stock, valued at approximately $1,722,633.06. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 66,368 shares of company stock worth $1,393,764. 28.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ACAD. Bain Capital Life Sciences Investors LLC lifted its position in shares of ACADIA Pharmaceuticals by 1.7% in the 3rd quarter. Bain Capital Life Sciences Investors LLC now owns 610,523 shares of the biopharmaceutical company’s stock valued at $9,988,000 after acquiring an additional 10,000 shares in the last quarter. Hohimer Wealth Management LLC grew its stake in ACADIA Pharmaceuticals by 26.5% in the 4th quarter. Hohimer Wealth Management LLC now owns 20,265 shares of the biopharmaceutical company’s stock valued at $323,000 after buying an additional 4,250 shares during the last quarter. Hennion & Walsh Asset Management Inc. grew its position in ACADIA Pharmaceuticals by 1.1% in the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 200,032 shares of the biopharmaceutical company’s stock worth $3,273,000 after purchasing an additional 2,117 shares during the last quarter. Gibson Wealth Advisors LLC grew its position in ACADIA Pharmaceuticals by 6,200.0% in the 4th quarter. Gibson Wealth Advisors LLC now owns 6,300 shares of the biopharmaceutical company’s stock worth $98,000 after purchasing an additional 6,200 shares during the last quarter. Finally, Emerald Mutual Fund Advisers Trust grew its position in ACADIA Pharmaceuticals by 1.6% in the 4th quarter. Emerald Mutual Fund Advisers Trust now owns 1,048,750 shares of the biopharmaceutical company’s stock worth $16,696,000 after purchasing an additional 16,011 shares during the last quarter. 92.79% of the stock is currently owned by institutional investors.

ACADIA Pharmaceuticals Company Profile

(Get Rating)

ACADIA Pharmaceuticals, Inc is a biopharmaceutical company, which focuses on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.